Early withdrawal of cyclosporine a improves 1-year kidney graft structure and function in sirolimus-treated patients

Transplantation

Volumn 75, Issue 7, 2003, Pages 998-1003

  Stallone, Giovanni ^a   Di Paolo, Salvatore ^a   Schena, Antonio ^a   Infante, Barbara ^a   Grandaliano, Giuseppe ^a   Battaglia, Michele ^a   Gesualdo, Loreto ^b   Schena, Francesco Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISONE; RAPAMYCIN;

ADULT; AGED; ARTICLE; BLOOD VESSEL INJURY; CADAVER KIDNEY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY INJURY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; REPERFUSION INJURY; STRUCTURE ACTIVITY RELATION;

EID: 0037446794     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000057240.95073.35     Document Type: Article

References (32)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
2. Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: The problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001; 71(11 suppl): SS42.
3. Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation 2000; 69(12 suppl): SS5.
4. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333.
5. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335.
6. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complex. Cell 1991; 66: 807.
7. Hong JC, Kahan BD. Two paradigms for new immunosuppressive strategies in organ transplantation. Curr Opin Organ Transplant 1998; 3: 175.
8. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
9. Morris RE, Meiser BM. Identification of new pharmacologic action for an old compound. Med Sci Res 1989; 17: 877.
10. Kahan BD, Gibbons S, Tejpal N, et al. Synergistic interaction of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232.
11. Stepkowski SM, Chen H, Daloze P, et al. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation 1991; 51: 22.
12. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.
13. Seron D, Moreso F, Fulladosa X, et al. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 2002; 61: 727.
14. Di Paolo S, Stallone G, Schena A, et al. Hypertension is an independent predictor of delayed graft function and worse renal function only in kidneys with chronic pathological lesions. Transplantation 2002; 73: 623.
15. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
16. Nankivell BJ, Gruenland SM, Allen RDM, et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
17. Kjeldsen SE, Erdine S, Farsang C, et al. 1999 WHO/ISH Hypertension Guidelines: Highlights & ESH update. J Hypertens 2002; 20: 153.
18. Cook NS, Zerwes HG, Rudin M, et al. Chronic graft loss: Dealing with the vascular alterations in solid organ transplantation. Transplant Proc 1998;30:2413.
19. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56: 783.
20. Sharma VK, Bologa RM, Xu GP, et al. Intragraft TGF-beta 1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996; 49: 1297.
21. Floege J, Hudkins KL, Davis CL, et al. Expression of PDGF alpha-receptor in renal arteriosclerosis and rejecting renal transplants. J Am Soc Nephrol 1998; 9: 211.
22. Gregory CR, Pratt RE, Huie P, et al. Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc 1993; 25: 770.
23. Morris RE, Cao W, Huang X, et al. Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and balloon-injured carotid arteries: Evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc 1995; 27: 430.
24. Suzuki T, Kojia G, Hayashi S, et al. Stent-based delivery of Sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188.
25. Walpoth BH, Pavlicek M, Celik B, et al. Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts. Eur J Cardiothorac Surg 2001; 19: 487.
26. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164.
27. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70: 969.
28. Braun-Dullaeus RC, Mann MJ, Seay U, et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001; 21: 1152.
29. Poston RS, Billingham M, Hoyt EG, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999; 100: 67.
30. Baboolal K, Jones GA, Janezic A, et al. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002; 61: 686.
31. Andoh TF, Lindsley J, Franceschini N, et al. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311.
32. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059.